Arsanis Inc., of Waltham, Mass., presented data from two of its preclinical programs demonstrating targeted protection in animal models against certain strains of Escherichia coli and Klebsiella pneumoniae. Read More
Summit Therapeutics plc, of Oxford, U.K., enrolled the first patient in Phaseout DMD, a phase II proof-of-concept trial of ezutromid (formerly SMT C1100) in patients with Duchenne muscular dystrophy (DMD). Read More
Innocoll Holdings plc, of Athlone, Ireland, said it priced an underwritten public offering of 5.725 million ordinary shares at $7 each, for aggregate gross proceeds of approximately $40.1 million. In addition, the company has granted the underwriters of the offering a 30-day option to purchase up to an additional 858,750 ordinary shares. Read More
TMEM230 mutations caused familial Parkinson's disease (PD), implicating synaptic vesicle trafficking in the disorder. PD symptoms result from the death of dopaminergic neurons in the substantia nigra, but the events leading up to cell death are still poorly understood. Read More
DUBLIN – Shares in Scancell Holdings plc fell over 16 percent Friday on news that the company had to bin supplies of its candidate DNA-based cancer vaccine SCIB1, as routine testing showed the clinical material no longer conformed to its original specification. Read More
Kids who play with letter and number puzzles for fun grow up to start venture capital firms with alphanumeric names. At least, that was the case for Adele Oliva, partner of 1315 Capital LLC, which just closed a $200 million inaugural fund. The Philadelphia-based firm invests in commercial-stage companies in the medical technology, specialty pharmaceutical and health care services sectors. Read More
As investors await top-line phase III data later this summer for AM-101, its lead program in tinnitus, Auris Medical Holding AG continued advancing its other late-stage candidate, AM-111, launching as planned a second phase III study in hearing loss. Both indications represent potential first-mover opportunities for the Swiss-based biopharma. Read More
Hoping to fill what chief medical officer (CMO) Evan Loh called "a vacuum of unmet need" created by the FDA's recent edict on the dangers of fluoroquinolone antibiotics, Paratek Pharmaceuticals Inc. aims to build on success with the first of two phase III registration trials comparing its once-daily, broad-spectrum antibiotic, omadacycline, to linezolid (Zyvox, Pfizer Inc.) for acute bacterial skin and skin structure infection (ABSSSI). Read More
